biologic

Enbrel

etanercept

Loss of exclusivityMarch 2032projected — 12-year biologic exclusivity estimate
CompanyImmunex Corporation

Drug detail

Brand nameEnbrel
Active ingredientetanercept
Strength25MG/0.5ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalMarch 2020
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Enbrel patent cliff — loss of exclusivity March 2032 | CliffBio